The latest glucagon-like peptide 1 (GLP-1) receptor agonists have been heralded for their potential to not only boost weight loss and glucose control but also improve cardiovascular, gastric, hepatic, and renal values
Carolyn Crist is a Health and Medical Independent Journalist. She focuses on various themes including medicine and healthcare, HR and workforce issues, and alternative medicine, often exploring topics like data, AI, and social issues. Carolyn's work has been featured in notable publications such as MDEdge, Cybersecurity Dive, WebMD, and Medscape.